CAMP Continuation Study/Phase 3

CAMP 继续研究/第 3 阶段

• 批准号: 7364889
• 负责人: ANNE L FUHLBRIGGE
• 金额: $ 24.14万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7364889
• 关键词: Adrenal Cortex Hormones; Adult; Age; Anti-Inflammatory Agents; Anti-inflammatory; Asthma; Breathing; Bronchodilation; Bronchodilator Agents; Child; Childhood; Childhood Asthma; Chronic Airflow Obstruction; Chronic Obstructive Airway Disease; Clinical; Data; Data Collection; Genetic; Genomics; Growth; Inflammation; Lung; Lung diseases; Measurement; Measures; Natural History; Normal Range; Parents; Participant; Patients; Pattern; Pharmaceutical Preparations; Phase; Phase III Clinical Trials; Phenotype; Population; Procedures; Pulmonary Function Test/Forced Expiratory Volume 1; Recruitment Activity; Respiratory physiology; Risk; Risk Factors; Spirometry; Subgroup; abstracting; aged; airway obstruction; cohort; cost; design; end of life; follow-up; genetic analysis; genetic risk factor; programs; size

DESCRIPTION (provided by applicant): CAMPCS/3 is designed to follow patients with persistent asthma from the Childhood Asthma Management Program (CAMP) trial for 4 additional years (through ages 21-29) to determine clinical and genetic risk factors for patterns of lung function decline indicative of chronic airflow obstruction in later adulthood. No other study of childhood asthma has the size, detailed phenotyping, and longitudinal follow-up needed to determine these risk factors. CAMP recruited 1041 persistent asthmatics to determine the effect of regular inhaled corticosteroid (ICS) on lung-growth. We are currently following 869 (83% of the original cohort) to determine predictors of attained maximal lung growth in early adulthood for persistent asthmatics. We have identified patterns of reduced growth arid evolving airway obstruction. Analysis of CAMP participants, aged 23 years or older, indicate that 28% did not reach normal maximal level of FEV1 even when measured after bronchodilation. We have also observed that 20% have already started to decline, with the mean age of decline 19.4 years. These abnormalities may be due to persistent inflammation suggestive of early chronic obstructive pulmonary disease. We propose 3 specific aims: 1) Define, using a range of normal comparison populations, susceptible subgroups of patients with persistent childhood asthma who are at risk for patterns of reduced attained maximal lung function and of subsequent decline of lung function, 2) Identify genetic correlates of maximal attained lung function and early lung function decline (genetic analyses will be done by Dr. Weiss and the Center for Genetics and Genomics at Harvard, without cost to this application) relating existing genetic data on more than 700 trios of parents and CAMP patients to the detailed phenotypic data collected during all phases of CAMP, and 3) Determine effects into early adulthood of 4-6 years of prior continuous treatment with inhaled anti-inflammatory medications. Data collection procedures for spirometry and other procedures will be identical to those used in previous phases of the CAMP study. Annual pre- and post-bronchodilator spirometry will allow accurate measurement of lung function. CAMP is the largest, most completely characterized cohort of children with asthma. Follow-up of this cohort in CAMPCS/3 will provide valuable information about the natural history of this important childhood lung disease, which can be used to identify patients with asthma who are at risk of chronic airflow obstruction later in adult life. (End of Abstract.)

描述（由申请人提供）： CAMCCS/3旨在跟随儿童哮喘管理计划（CAMP）试验（CAMP）试验（至21-29岁）的持续性哮喘患者，以确定肺功能下降模式下降的临床和遗传风险因素，这表明成年后期慢性气流阻塞。没有其他对儿童哮喘的研究具有确定这些危险因素所需的大小，详细的表型和纵向随访。 CAMP招募了1041次持续性哮喘患者，以确定常规吸入皮质类固醇（IC）对肺增长的影响。目前，我们遵循869（占原始队列的83％），以确定成年初期达到最大肺部生长的预测因子。我们已经确定了降低生长的气道阻塞的模式。对23岁以上的营地参与者的分析表明，即使在支气管扩张后测量时，28％也没有达到FEV1的正常水平。我们还观察到20％的人已经开始下降，平均年龄为19.4岁。这些异常可能是由于持续的炎症暗示了早期慢性阻塞性肺部疾病。我们提出了3个具体目的：1）定义，使用一系列正常的比较人群，持续的儿童哮喘患者的易感亚组，他们处于肺部最大肺功能降低的风险和随后的肺功能下降的风险下，2）识别肺部的最大遗传和早期的遗传学作用（WEIS基因疾病，均具有遗传性的基因性，并确定基因的遗传学作用。哈佛，无需花费本应用的费用）将700多个父母和cAMP患者的现有遗传数据与在CAMP所有阶段收集的详细表型数据相关，3）确定对入射抗炎药的持续不断治疗的成年早期的影响。肺活量测定法和其他程序的数据收集程序将与CAMP研究的先前阶段中使用的数据相同。年度前后支气管缓解液肺活量测定法将允许对肺功能进行准确的测量。营地是哮喘儿童的最大，最完全特征的人群。对CAMCC/3中此队列的后续措施将提供有关这种重要的童年肺部疾病的自然历史的宝贵信息，该疾病可用于识别哮喘患者，他们有慢性气流障碍的风险后期成人生活。 （摘要结束。）